Nebivolol Evolugen (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivolol Evolugen, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and heart failure in adult patients. GNH USA supplies Nebivolol Evolugen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol Hydrochloride acts on the cardiovascular system to lower blood pressure and improve cardiac output. - Hypertension: reduces systolic and diastolic pressure, helping to achieve target blood pressure goals. - Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure.

Nebivolol Hydrochloride may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness or light‑headedness: related to blood‑pressure reduction. - Fatigue: generalized tiredness, especially during dose titration. - Bradycardia: heart rate below 60 bpm in some patients.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute bronchospasm in patients with underlying airway disease. - Hepatic injury manifested by elevated transaminases. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Nebivolol Hydrochloride requires careful monitoring and patient education before and during treatment. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Cardiac assessment: evaluate heart rate and ECG, especially in patients with conduction disorders. - Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent additive effects. - Renal/hepatic impairment: dose adjustment may be needed in moderate to severe dysfunction. - Discontinuation: do not stop abruptly; taper under medical supervision to prevent rebound hypertension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol Hydrochloride can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Calcium‑channel blockers (verapamil, diltiazem): may cause marked bradycardia or AV block. - CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): increase nebivolol plasma levels. - Other antihypertensives (ACE inhibitors, ARBs) used in high doses: risk of additive hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension; monitor electrolytes. - NSAIDs: can blunt antihypertensive effect; assess blood pressure response. - Antidiabetic agents: nebivolol may mask hypoglycaemia symptoms; monitor glucose levels.